Form 4: Precision BioSciences CEO Michael Amoroso Executes Stock Transactions Following RSU Vesting

Precision BioSciences CEO Michael Amoroso acquired shares through RSU vesting and sold a portion to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Michael Amoroso, CEO of Precision BioSciences, engaged in transactions involving the company's common stock.
• On January 20, 2025, Mr. Amoroso acquired 115,388 shares through the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on three separate dates and vest in three annual installments.
• On January 21, 2025, Mr. Amoroso sold 36,838 shares at a price of $4.67 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 2, 2024.
• The shares were sold solely to cover tax withholding obligations related to the RSU vesting.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices and tax-related sales, which are generally neutral. The use of a 10b5-1 plan adds a layer of predictability.

Positives

• The vesting of RSUs indicates that performance milestones were likely met.
• The CEO's continued service is required for the vesting of the RSUs, aligning his interests with the company's long-term success.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• The sale of shares by a key executive, even for tax purposes, could create short-term price volatility.
• The reliance on Rule 10b5-1 plans can sometimes obscure the true sentiment of insiders.

Management Comments

• The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

This type of transaction is common for executives who receive equity compensation, and the use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among publicly traded companies to manage insider stock sales.
• The vesting schedules for RSUs are typical, often occurring over a three-year period.
• The sale of shares to cover tax obligations is a standard practice for executives receiving equity compensation.

Stakeholder Impact

• Shareholders may view the sale of shares by the CEO as a negative signal, although it is for tax purposes.
• Employees may see the vesting of RSUs as a positive sign of company performance.

Key Dates

Keywords

Precision BioSciences, Michael Amoroso, SEC Form 4, Restricted Stock Units, RSU, Rule 10b5-1, insider trading, stock sale, vesting